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OBJECTIVE — TocomparetheglucosevariabilityassociatedwithinsulinglargineandNPH/
Lente insulin used as the basal insulin component of a multiple daily injection (MDI) regimen in
pediatric patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS — Continuous glucose monitoring data were
collected from a subset of patients (n  90) who agreed to use a continuous glucose monitoring
system during an active-controlled, randomized, open-label study evaluating the safety and
efﬁcacy of insulin glargine and NPH/Lente insulin used with insulin lispro as part of an MDI
regimen.
RESULTS — Treatment with insulin glargine resulted in signiﬁcant reductions in glucose
variabilityasmeasuredbytheSDofglucosevalues(adjustedmeanchangefrombaselinetoweek
24: 13.4 mg/dl [0.74 mmol/l]; P  0.05), mean amplitude of glycemic excursion (34.4
mg/dl [1.91 mmol/l]; P  0.0001), and M value (9.6 mg/dl [0.53 mmol/l]; P  0.03). The
corresponding reductions in glucose variability for NPH/Lente were not signiﬁcant.
CONCLUSIONS — Insulinglargineisassociatedwithgreaterreductionsinglucosevariabil-
ity than NPH/Lente insulin in pediatric patients with type 1 diabetes.
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I
mproved glycemic control to prevent
or delay microvascular complications
isofparamountimportanceinchildren
and adolescents with type 1 diabetes but
is often achieved at the price of increased
hypoglycemia (1,2). Persistent wide ﬂuc-
tuationsinplasmaglucoseinthepresence
of lower mean glucose and A1C values
may be an important reason why inten-
sive therapy, as practiced in the Diabetes
Control and Complications Trial, in-
creases the risk of severe hypoglycemia
(2,3). Several studies have suggested that
glycemic variability may also play an in-
dependent role in the development of di-
abetes complications (4–8). Therefore,
someinvestigatorssuggestthatbloodglu-
cose variability, when combined with
A1C levels, is an important indicator of
glycemic control and the risk for long-
term complications (9,10).
Insulin glargine (Lantus; sanoﬁ-
aventis U.S., Bridgewater, NJ) is a basal
insulin with little or no pronounced ac-
tionpeakandlimitedsiteabsorptionvari-
ation (11). Its use as part of a multiple
daily injection (MDI) regimen demon-
strated good glucose control with less hy-
poglycemia than NPH insulin in adults
with type 1 or type 2 diabetes (12,13).
However, only one major randomized
clinical trial in pediatric patients has ex-
amined the relative efﬁcacy of insulin
glargine–based MDI versus MDI regi-
mens utilizing intermediate-acting insu-
lins, and this study did not examine
glucose variability (14).
Consequently, we performed a large
randomized clinical trial in adolescents
withtype1diabetestocomparethesetwo
approachestointensiveinsulintherapy.A
secondaryaimofthistrialwastocompare
the glucose variability using insulin
glargine with that using intermediate-
acting insulin (NPH or Lente) as the basal
insulin component of an MDI regimen.
Both patient groups received premeal in-
sulin lispro (Humalog; Eli Lilly and Co.,
Indianapolis, IN). This study reports the
results of data analysis from a subset of
patients who volunteered to use a contin-
uous glucose monitoring system (CGMS)
to assess glucose variability. Results from
the entire randomized controlled trial are
reported elsewhere (15).
RESEARCH DESIGN AND
METHODS— The study design and
methods have been described previously
(15). Patients with type 1 diabetes (n 
175) participated in this randomized
study comparing insulin glargine and
NPH/Lente insulin, each used with pre-
meal insulin lispro in an MDI regimen. A
subsetofpatients(glargine,n74;NPH/
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CGMS (Medtronic/MiniMed, Northridge,
CA), which measures interstitial glucose
concentrations every 5 min for 3 days via
aglucoseoxidase–basedmethod,tocom-
pare variability in interstitial glucose lev-
els across the two regimens. CGMS
accuracy has been demonstrated to be
similar from day to day (16). The median
relative absolute difference between sen-
sor and reference plasma glucose values
in children with type 1 diabetes has been
11% during outpatient use (17). In this
study, patients and the health care team
were blinded to CGMS results, which
were not used for diabetes management
but only for the assessment of glycemic
variability.
Eligibility criteria and baseline
characteristics
Patients aged 9–17 years with type 1 dia-
betes (for 1 year), at Tanner stage 2
puberty,withA1Clevel7.0–9.5%,andat
least two insulin injections per day or
continuous subcutaneous insulin infu-
sion were enrolled. Excluded were pa-
tients with diabetic ketoacidosis in the
past 3 months or two or more episodes of
severe hypoglycemia (i.e., an event re-
quiring the assistance of another person
and accompanied by either a blood glu-
coselevelof36mg/dl[2.0mmol/l]or
prompt recovery after oral carbohydrate
intake, intravenous glucose, or glucagon
administration) in the past 12 months.
Patients had to be willing to perform self-
monitoring of blood glucose (SMBG) at
least four times daily. The CGMS sub-
group had to be willing to use the Mini-
Med CGMS for up to 3 consecutive days
on three occasions.
Study medication
Patients were randomized to receive ei-
ther basal insulin glargine once daily be-
fore breakfast or intermediate-acting
insulin (NPH or Lente) twice daily; start-
ing doses were 40–50% of the total daily
insulindose.Bothgroupsreceivedinsulin
lispro before each meal based on carbo-
hydrate intake, with individualized cor-
rection doses based on the degree to
which blood glucose levels deviated from
the target glucose values.
Continuous glucose monitoring
Interstitial glucose was measured during
threeperiods(week0,week12,andweek
24) for 3 consecutive days each. Patients
were to enter at least four SMBG values
daily to calibrate the CGMS and to record
important events (e.g., insulin boluses,
snacks, and exercise).
Measures of glycemic control and
glycemic variability
Glycemic control was assessed by A1C at
baseline, 12 weeks, and 24 weeks and by
the time CGMS glucose values were 70,
50, 40, 250, and 350 mg/dl
(3.89, 2.78, 2.22, 13.88, and
19.45 mmol/l) (refer to Table 1). A1C
was measured using ion-exchange high-
performanceliquidchromatographywith
the Bio-Rad Variant II Turbo analyzer
(Bio-Rad, Hercules, CA). The system was
certiﬁed by the National Glycohemoglo-
bin Standardization Program with values
traceable to the Diabetes Control and
Complications Trial reference method;
the reported normal range is 4.27–
6.07%, with coefﬁcients of variation of
1.94and2.58%atA1Cvaluesof6.25and
12.5%, respectively.
Measures of glucose variability from
the CGMS were 1) SD of the mean of the
sensor values, 2) mean amplitude of gly-
cemic excursion (MAGE) (18,19), and 3)
M value, which is expressed by the for-
mula below (19).

N 10 log
Sensor glucose
120 
3

Max  Min Sensor glucose
20 
Table 1—Adjusted mean change from baseline in time spent above or below speciﬁed sensor glucose levels in CGMS subset
Insulin glargine NPH/Lente Difference
n
Sample mean
(min/day) P vs. baseline n
Sample mean
(min/day) P vs. baseline
Adjusted
mean P
70 mg/dl (3.89 mmol/l)
Baseline 45 119.0 45 75.5
Week 12 39 141.0 0.1067 35 94.8 0.7013 30.4 0.4040
Week 24 33 64.2 0.0983 36 85.3 0.5931 46.6 0.1163
50 mg/dl (2.78 mmol/l)
Baseline 45 25.1 45 18.2
Week 12 39 54.0 0.0288 35 38.6 0.1508 10.9 0.6315
Week 24 33 13.4 0.5246 36 39.8 0.0083 38.2 0.0198
40 mg/dl (2.22 mmol/l)
Baseline 45 12.7 45 6.9
Week 12 39 27.4 0.0832 35 21.6 0.2550 5.9 0.7089
Week 24 33 3.0 0.3597 36 23.8 0.0092 26.9 0.0130
250 mg/dl (13.88 mmol/l)
Baseline 45 397.3 45 415.4
Week 12 39 289.9 0.0220 35 408.3 0.7453 93.8 0.1756
Week 24 33 302.1 0.0347 36 390.9 0.4545 69.2 0.3013
350 mg/dl (19.43 mmol/l)
Baseline 45 107.0 45 106.9
Week 12 39 54.4 0.0126 35 109.2 0.7910 56.7 0.1214
Week 24 33 66.6 0.0709 36 87.9 0.2916 18.1 0.5523
Glargine and NPH/Lente glucose variability
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50, 40, 250, and 350 mg/dl
(3.89, 2.78, 2.22, 13.88, and
19.45 mmol/l) were calculated.
ForCGMSdatatobeanalyzable,each
patient had to have a sufﬁcient duration
(i.e., 24 h of sensor data for each day) of
CGMSdataandadateforCGMSdatacol-
lection at the appropriate time in the
study. Some patients in the insulin
glargine(n29)andtheNPH/Lente(n
30) groups were excluded from the anal-
ysis because of discrepancies between
CGMS and SMBG values recorded by the
same patient, unfamiliarity with the me-
chanics of the CGMS, or technical prob-
lems during CGMS measurement. Forty-
ﬁvepatientsineachgrouphadanalyzable
data at baseline and at any end point, and
33 patients in the glargine group and 36
in the NPH/Lente group had data at base-
line and week 24.
RESULTS— Study results from the
overall trial are reported elsewhere (15).
In summary, change in A1C level from
baselineto24weekswas0.250.14%
for the glargine group (n  76) and
0.050.13%fortheNPH/Lentegroup
(n  81); these changes were not signiﬁ-
cant (P  0.1725). However, repeated-
measures analysis showed a greater
reductioninA1Clevelassociatedwiththe
useofinsulinglargineinpatientswhohad
higher baseline A1C values (for median
and 90th percentile values; P  0.05 be-
tween groups). Rates of glucose readings
70 mg/dl (3.88 mmol/l) (per patient-
year) were 116.1 and 93.8 in the glargine
and the NPH/Lente group, respectively
(P  0.030), whereas rates of glucose
50 mg/dl (2.78 mmol/l) (21 in glargine
group vs. 20 in NPH/Lente group; P 
0.81) and 36 mg/dl (2.0 mmol/l) (1.2
vs. 1.7; P  0.32), severe hypoglycemia
(0.20 vs. 0.09; P  0.18), and treatment-
emergent adverse events (17.6 vs. 8.9%;
P  0.12) did not differ signiﬁcantly be-
tween groups.
Patient characteristics at baseline
There were no signiﬁcant differences in
baseline characteristics between patients
who used the CGMS and the entire study
population (Table 2). There also was no
signiﬁcant difference between the main
study group and CGMS subgroup with
respecttochangesinA1Clevelduringthe
trial (Table 1).
Glycemic outcomes
In the CGMS subgroup, the adjusted
mean change in A1C level from baseline
to end point was 0.12% and 0.10%
for glargine versus NPH/Lente, respec-
tively (P  0.9250). A1C outcomes and
hypoglycemia rates (events per patient-
year, determined by glucose meter mea-
surements) in the CGMS subgroup
paralleled those in the overall study (15).
Continuous glucose monitoring
values and variability
Mean glucose value. There were no be-
tween-group differences in mean 24-h
glucoseconcentrations(Table3;Fig.1)or
the glucose concentrations analyzed in
6-hintervalsthroughouttheday(datanot
shown).
SD of glucose. Subjects using insulin
glargineshowedasigniﬁcantreductionin
glucose variability (as measured by SD)
from baseline (P  0.0001 for each time
point) and a signiﬁcantly greater reduc-
tion at week 24 than those using NPH/
Lente (P  0.0147) (Table 3; Fig. 2A).
Those using NPH/Lente had a trend for
reduction in SD from baseline at week 12
(P  0.0503) but not at week 24 (P 
0.4286) (Table 2; Fig. 2A).
Table 2—Demographics, baseline characteristics of randomized patients, and CGMS subpopulation (ref. 24)*
Study population CGMS subpopulation
Insulin
glargine NPH/Lente
Insulin
glargine NPH/Lente
n 85 90 45 45
Age (years) 13.1  2.4 13.4  2.4 13.2  2.3 13.4  2.5
Sex (female) 45 (53.6) 44 (52.4) 23 (51.1) 19 (42.2)
Race/ethnicity
Caucasian 71 (84.5) 68 (81.0) 41 (91.1) 40 (88.9)
African American 0 (0.0) 7 (8.3) 0 (0.0) 0 (0.0)
Asian 2 (2.4) 2 (2.4) 0 (0.0) 2 (4.4)
Hispanic 7 (8.3) 2 (4.8) 3 (6.7) 2 (4.4)
Multiracial/multiethnic 2 (2.4) 1 (1.2) 1 (2.2) 0 (0.0)
Other 2 (2.4) 2 (2.4) 0 (0.0) 1 (2.2)
Weight (kg) 57.2  14.8 59.1  18.1 57.9  15.1 57.8  19.4
BMI (kg/m
2) 22.6  3.8 22.9  5.0 22.6  0.8 22.6  0.9
Age at onset (years) 8.5  3.5 8.5  3.7 8.3  3.7 9.0  3.5
Duration of diabetes (years) 5.1  3.4 5.4  3.7 5.4  3.7 4.9  3.6
A1C (%)
Baseline 7.8  0.8 8.0  0.8 7.9  0.9 8.0  0.8
Adjusted baseline
A1C 10th percentile 7.28 7.12 7.28 6.95
A1C median percentile 7.74 7.86 7.82 7.84
A1C 90th percentile 8.32 8.79 8.51 8.97
Baseline fasting SMBG (mg/dl) 188.5  54.4 203.0  52.1 187.4  62.5 203.4  42.3
Data are means, means  SD, or n (%). Adjusted mean values of A1C are at study end in relation to baseline values. *No signiﬁcant differences between groups who
did or did not participate in CGMS.
White and Associates
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in the insulin glargine group at weeks 12
(P  0.0001) and 24 (P  0.0001) com-
pared with baseline (Table 2). The ad-
justed mean change from baseline in
MAGE for NPH/Lente-treated patients
was not signiﬁcant at week 12 (P 
0.1139) or 24 (P  0.7459). The be-
tween-group difference in adjusted mean
change in MAGE from baseline favored
glargine at week 12 and was signiﬁcant at
week 24 (P  0.0055) (Fig. 2B).
M value. Although between-group dif-
ferences in the adjusted mean reduction
in M value were not statistically signiﬁ-
cant (Fig. 2C), insulin glargine–treated
patients experienced signiﬁcant reduc-
tions from baseline at weeks 12 (P 
0.0309) and 24 (P  0.0048) (Table 3).
The adjusted mean change from baseline
in the NPH/Lente group was not signiﬁ-
cant (P  0.8440 and P  0.7360 at 12
and 24 weeks, respectively).
Hypoglycemia and hyperglycemia as
determined by CGMS
Compared with NPH/Lente, insulin
glarginetherapyreducedthetimespentat
glucose levels 70, 50, and 40 mg/dl
(3.89, 2.78, and 2.22 mmol/l) be-
tween baseline and week 24 (Table 1).
Differencesinadjustedmeanchangefrom
baseline were statistically signiﬁcant for
insulin glargine for glucose levels 50
mg/dl (2.78 mmol/l; P  0.0198) and
40 mg/dl (2.22 mmol/l; P  0.0130).
Insulinglarginealsosigniﬁcantlyreduced
the time spent at glucose levels 250 and
350 mg/dl (13.88 and 19.43
mmol/l) between baseline and week 12
(P  0.0220 and P  0.0126, respec-
tively); at week 24, time spent 250
mg/dl (13.88 mmol/l) was also signiﬁ-
cantlyreduced(P0.0347),butthetime
spent 350 mg/dl (19.43 mmol/l; P 
0.0709) was not. For NPH/Lente, time
spent 350 mg/dl (19.43 mmol/l) or
250 mg/dl (13.88 mmol/l) was not
reducedat12or24weeks,andtherewere
no between-group differences (P 
0.1214–0.5523 for all).
CONCLUSIONS— The most impor-
tant ﬁnding of this substudy was that pe-
diatric patients receiving insulin glargine
appeared to experience less variability in
glucose levels, as assessed by SD and
MAGE, than patients receiving NPH/
Lente insulin. Reductions in glycemic
variability may have important clinical
implications, including tighter glycemic
controlwithlessriskofhypoglycemiaand
a reduction in vascular complications
(3,19). Cox et al. (20) found that high
glucose variability precedes severe hypo-
glycemia, suggesting that reducing glu-
cose ﬂuctuations may reduce the risk for
severe hypoglycemia. Hypoglycemia lim-
itstheabilitytocontrolbloodglucoseand
A1C levels in insulin-treated diabetes
(21).Increasedglycemicvariability,inde-
pendently of average blood glucose and
A1C levels, is believed by some to con-
tribute to vascular complications (22,23).
Thus, information on variability of
blood glucose may become increasingly
important to clinicians and patients in
the future; CGMS may serve as a valu-
able tool for assessing the overall level
of glycemic control beyond what can be
determined by measuring A1C levels
alone. The CGMS with masked 5-min
sampling used in this study provides a
better estimate of the magnitude of glu-
coseexcursionsthantheﬁxed-point-in-
time 8-point testing procedures used in
other studies (3).
In the CGMS subpopulation in this
study, despite similar reductions in A1C
(0.12 vs. 0.10%), the adjusted mean
difference from baseline at 24 weeks in
time spent at glucose levels of 40 and
50 mg/dl (2.22 and 2.78 mmol/l)
by patients using insulin glargine was sig-
niﬁcantly less than time spent by those
using NPH/Lente (13.4 vs. 39.8 min/day,
P  0.0198 for glucose 50 mg/dl
[2.78 mmol/l]; and 3.0 vs. 23.8 min/
day, P  0.013 for glucose 40 mg/dl
[2.22 mmol/l]). The time spent 70
mg/dl was similar between groups (64.2
vs. 85.3 min/day; P  0.1163) (Table 1).
In both groups there was an initial trend
for an increase in time at each hypoglyce-
mia threshold at week 12, followed by a
reduction by week 24, as noted above.
This increase may reﬂect the initial upti-
tration of insulin doses at the start of the
study, followed by stabilization of doses.
There were too few severe hypoglycemic
events to allow identiﬁcation of differ-
Table 3—Mean CGMS sensor values and variability measures at baseline and weeks 12 and 24
Insulin glargine NPH/Lente
P for difference* n
Sample mean
(mg/dl) P vs. baseline n
Sample mean
(mg/dl) P vs. baseline
Mean CGMS sensor values
Baseline 45 190.6 45 197.1
Week 12 39 177.3 0.0728 35 195.4 0.6759 0.3516
Week 24 33 181.8 0.2228 36 195.3 0.6371 0.5745
SD
Baseline 45 77.4 45 73.9
Week 12 39 63.8 0.0001 35 71.2 0.0503 0.0509
Week 24 33 64.2 0.0001 36 74.3 0.4286 0.0147
MAGE
Baseline 45 188.5 45 177.7
Week 12 39 154.7 0.0001 35 173.6 0.1139 0.1051
Week 24 33 152.0 0.0001 36 182.0 0.7459 0.0055
M value
Baseline 45 43.5 45 43.2
Week 12 39 36.8 0.0309 35 43.7 0.8440 0.1768
Week 24 33 34.2 0.0048 36 42.3 0.7360 0.0631
*Difference in adjusted mean change between groups.
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390 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009Figure 1—Mean (1 SE) CGMS curves in patients with at least one 24-h CGMS recording at the following time points: baseline (A), week 12 (B),
and week 24 (C) for those in the glargine group (green) and the NPH/Lente group (blue).
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correlates were evaluated.
Although the CGMS subgroup in the
current study was similar to the overall
study population in terms of demograph-
ics, one limitation of this analysis is the
possibility that the CGMS subgroup may
have been different from the overall pop-
ulation, based on unmeasured variables,
Figure 2—Adjusted mean change from baseline in measures of glucose variability associated with insulin glargine and intermediate-acting insulin
(NPH/Lente). A: SD; *P  0.05 from baseline; †P  0.0503 from baseline. B: MAGE; *P  0.0001 from baseline. C: M value; *P  0.04 from baseline.
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and other behavioral differences that can
affect disease management. Whereas all
patients had to have at least Tanner stage
2 pubertal development to enter the
study,theimpactofdifferentstagesofpu-
bertal development on glycemic control
andglucosevariabilitycouldnotbedeter-
mined from the data collected.
Inconclusion,theresultsofthisstudy
suggest that the use of insulin glargine as
the basal component of a multiple injec-
tion regimen appears to be associated
with a reduction in glycemic variability.
In addition, to the extent to which re-
duced glycemic variability may contrib-
ute to a decrease in diabetes-related
complications, the use of insulin glargine
may be beneﬁcial.
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